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Neopterin  is a  pyrazino-pyrimidine compound derived from GTP.  It repre- 
sents an intermediate product in the synthetic pathway of biopterin.  Biopterin 
itself is known to serve as an essential cofactor in neurotransmitter synthesis (1, 
2).  We have recently observed that immune responses in vitro and in vivo are 
invariably accompanied by increased neopterin levels. In vitro release of neop- 
terin from human peripheral blood mononuclear cells (pbmnc) ~ was induced by 
stimulation with alloantigens, virally or chemically modified autologous cells or 
with  mitogenic lectins (3).  In  vivo-increased  neopterin  excretion  was  demon- 
strated  in  patients  suffering from  infections with  viruses  (4)  and  intracellular 
bacterial  or  protozoal  pathogens  (5,  6),  from  rheumatoid  arthritis  (RA)  and 
systemic lupus erythematosus (SLE) (7) and from acute cellular graft rejection 
or  graft-vs.-host  disease  (3,  8,  9).  Elevated  neopterin  levels  were  also  seen  in 
patients with acquired immunodeficiency syndrome (AIDS) (10) and in certain 
tumor  states  (4).  In  these  diseases  an  increase  of neopterin  excretion  usually 
precedes  the  clinical  manifestation  and  is  correlated  with  the  activity of the 
underlying disease.  This  behavior  qualified neopterin as a  useful tool  for the 
biochemical monitoring of certain diseases. In fact, daily evaluation of neopterin 
excretion is now an essential component of the clinical monitoring of allograft 
recipients in several institutions. This study aimed to elucidate the cellular basis 
of  the  immune  response-associated  neopterin  release  in  vitro.  We  present 
evidence that upon stimulation with factors derived from activated T  cells human 
monocytes and  macrophages  (M4~) release  neopterin  into culture  supernatants 
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and that interferon-gamma is the most active principle inducing this phenome- 
non. 
Material and Methods 
Reagents.  Medium RPMI 1640 (Gibco Laboratories, Grand Island, NY) supplemented 
with 20 mM of Hepes buffer (Gibco  Laboratories, Grand Island, NY), antibiotics, and 
15% heat-inactivated (56°C, 60 min) male pool serum was used throughout this study. 
Human nonrecombinant interferons a,/3, and ~, were obtained from Interferon Sciences 
and HEM Research (York Biological  Intern., NJ) and from Virogen, Basel, Switzerland. 
Human recombinant interferons a~ and ~, as well as neutralizing monoclonal antibodies 
were obtained from Bender & Co. Vienna, Austria. 
Mitogenic lectins phytohemagglutin (PHA), concanavalin A  (Con A), and pokeweed 
mitogen  (PWM)  as  well  as  lipopolysaccharide (LPS)  were  from  Pharmacia,  Uppsala, 
Sweden. Zymosan beads were obtained from Sigma Chemical Co. (St.  Louis, MO) and 
were incubated at a concentration of 1 mg/ml with fresh human serum for 60 min at 
37°C before use. 
Cell Separation Techniques.  Pbmnc were separated on Lymphoprep (Nygaard, Oslo, 
Norway). T cells and monocytes were isolated from heparinized venous blood of healthy 
volunteers by the  combined  use  of Percoll  gradient centrifugation and  passage  over 
Sephadex G 10 (Pharmacia, Uppsala, Sweden) columns or adherence on glass petri dishes 
as previously described (11). B cells were obtained from single cell suspensions  of human 
tonsils by negative selection with the pan-T cell monoclonal antibody T  101  and rabbit 
complement. Large granular lymphocytes (LGL) were enriched on Percoll density gra- 
dients as previously published (12). Purity of all cell populations except for LGL exceeded 
95% and for LGL, 75%. 
Cell Cultivation Techniques.  1 ×  106 pbmnc, T  cells, B cells, and LGL as well as 2.5 × 
105  monocytes were  cultured  in  2.0  ml  complete  tissue  culture  medium  in  Costar 
macroplates (Costar,  Cambridge,  MA).  They were  stimulated for various times  with 
mitogenic lectins,  allogeneic pbmnc (1  ×  106 cells) or lymphoblastoid cell lines (LCL) (2 
×  10 ~ cells), K 562 tumor cells (2 ×  105 cells), and with LPS (10 #g/ml) and complement- 
coated zymosan beads. Supernatants were harvested and were assessed in parallel studies 
for their neopterin content with high performance liquid chromatography (HPLC) and 
for their capacity to induce neopterin release from unstimulated cells. 
Measurement of Neopterin in Culture Supernatants.  Neopterin contents were measured 
from culture supernatants by means of HPLC according to our previously published 
method (13) using an automatized system device (Neopterin System, Varian Intern., Zug, 
Switzerland). 
Results 
Neopterin  Is  Released from  Human  M4~  and  Monocytes  upon  Stimulation  with 
Factors Derived from Activated  T  Cells.  We have previously shown that human 
pbmnc upon stimulation release considerable amounts of neopterin into culture 
supernatants (reference 3, see also Table I). Further experiments with adherent 
cell-depleted responder lymphocytes at that time suggested that T  cells might 
be responsible for this phenomenon (3). However, if T  cells, rigorously depleted 
of monocytes by combined use of Percoll density fractionation and passage over 
Sephadex G10  columns or by cloning and expansion in  IL-2,  were tested, no 
more neopterin was detected (Table I). Seemingly, B cells, suspensions enriched 
for LGL or monocytes, and Mq~ did not release measurable amounts of neopterin 
(Table  I).  Macrophages  stimulated with  supernatants  from  activated but  not 
from resting T  cells demonstrated strong neopterin production, which on a per 
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TABLE  I 
Neopterin Is Released  from Macrophages upon Stimulation with Factors Derived  from 
Activated T Cells 
Cell type*  Activated with:  No. of  Neopterin 
experiments  release* 
pbmnc 
T cells 
B cells 
LGL 
M~ 
29  <1 
PHA (1 t~g]ml), Con A (10 #g/ml)  26  10 ± 2 
AIIogeneic cells (LCL or pbmnc)  84  23 ± 5 
q~  11  <1 
PHA (1 ~g/ml),  Con A (10 t~g/ml)  4  <1 
Allogeneic cells (LCL)  16  <1 
Macrophage  supernatants  3  <1 
3  <1 
PWM (25 t~g/ml) and irradiated  T cells  3  <1 
3  <1 
K 562 cells  3  <1 
31  <1 
PHA (1 ,ug/ml), Con A (10 t*g/ml)  7  <1 
Allogeneic cells (LCL)  14  <1 
LPS (10 t~g/ml)  1  < 1 
Zymosan, C'coated (1 mg/ml)  3  <1 
Supernatants from resting T cells (25%)  14  <1 
Supernatants from alloreactive T  cell  7  <1 
clones, not restimulated  (12.5%) 
Supernatants from alloantigen-activated  27  22 ± 2 
T cells (25%) 
Supernatants from alloreactive T cell  17  10 ± 2  ! 
clones, restimulated  (12.5%) 
Supernatants from PHA or Con A re-  25  25 :l: 2 
stimulated  T cells (25%) 
* pbmnc, T  cells, LGL, and MS were isolated from the blood as described  in Materials and Methods. B cells were 
obtained from tonsils  by  negative  selection  with  anti-T cell antibodies  and  complement as also  detailed  in 
Materials and Methods.  1 x  10  e pbmnc, B cells, T  cells and LGL or 2.5  X 105 Mq~ were cultured in a total 
volume of 2.0 ml of complete  medium. 
* pmol/ml supernatant after 72-144 h of cultivation following activation, mean + mes. 
| Only 5 of 17 clones tested produced detectable  amounts of neopterin; data from these 5 clones are given in the 
table. 
were approximately  three times more effective as freshly isolated blood mono- 
cytes (three experiments,  data  not shown).  A  comparable release of neopterin 
was also seen from monoclonal M¢ derived from a patient with well-differentiated 
monocytic leukemia (data not shown).  Release of neopterin  from activated M4~ 
started after 24 h  and was maximal after 2-3 d.  Release of neopterin-inducing 
factors  from  T  cells  occurred  within  24  h  after  stimulation,  was  resistant  to 
irradiation  of up to 2,000 rads, was optimal at a  serum concentration  of 1%  in 
the culture,  and  could be completely blocked by addition  by cyclosporin A  at 
doses above 0.5  #g/mi;  factors were nondialyzable  and  sensitive  to  treatment 
with pronase or acid at a  pH of 2.0 (each observation is supported by at least 
three experiments, data not shown). As little as 1% of supernatant from activated 
T  cells induced measurable release of neopterin from M4~ and 25% was optimal 
in all 52 experiments performed. 
Interferon-gamma  Is  the Active  Principle  in  Supernatants  of Activated  T  Cells 
Responsible for Induction  of Neopterin  Release from M~.  Data  discussed in  the 
previous paragraph  indicated that  only the activation of M4~ with supernatants 
of transformed lymphocytes leads to release of neopterin.  This observation and 
the blocking effect of cyclosporin A suggested that lymphokine(s) might represent 
the active  principle(s)  contained  in  these  supernatants.  First  evidence for this HUBER ET AL.  313 
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FxCuaE  1.  Induction of neopterin release from M~ by various human interferons. 2.5 x  105 
M~ were cultured in 2.0 ml complete tissue culture medium in Costar macroplates. Various 
amounts of human interferons were added and the supernatants were harvested and assessed 
for neopterin content after 72 h. (O) nonrecombinant  IFNa (7 experiments), (0) recombinant 
IFNa2 (12 experiments), A nonrecombinant  IFNfl (14 experiments), [] nonrecombinant  IFN3, 
(3 experiments), •  recombinant IFN7 (t 8 experiments). 
view  was  obtained  in  experiments  in  which  various  human  interferons  were 
directly added to M~b. Data are demonstrated  in Fig.  1; they demonstrate  that 
IFN~ is a  most potent inducer of neopterin  release.  As little as  1 U  hut IFN3, 
induced an already measurable amount of neopterin, whereas approximately 10 a 
times  higher  concentrations  of hut  IFNa2  were required  for  this  effect.  The 
capacity of the latter to induce neopterin  release was also confirmed in in vivo 
studies: hur IFNa~ in doses above 5 X 106 U within 24 h induced a sharp increase 
of neopterin excretion in 5 of 5 tumor patients studied (results not shown). 
Maximal in vitro release of neopterin in the order of magnitude and with the 
kinetics of that induced by crude T  cell supernatants was achieved by physiolog- 
ical doses of hur  IFN3, in the range of 10 ~ to  10  ~ U/ml.  Further experimental 
support for the role of IFN3, as the crucial component in T  cell supernatants was 
obtained in neutralization  studies involving acidification and specific antibodies. 
We first observed that  acidification  of T  cell supernatants  at pH values of 2.0 
drastically reduced  their  capacity to induce  neopterin  release  from  M4~ (three 
experiments, data not shown). Secondly, monoclonal antibodies against hur IFN~ 
but not against IFNa~ or against IFNa2o~4 were able to completely neutralize the 
induction of neopterin release and this neutralization  could be overcome by re- 
addition of hur IFNT.  Data of one such experiment are demonstrated in Table 
II. 
Discussion 
Our  original  observation of elevated neopterin  excretion  in context with  in 
vivo and  in  vitro immune  stimulation  prompted  two different lines of further 
investigations: first, to assess the clinical utility of this biochemical marker in the 
monitoring  of and the screening for certain  diseases accompanied by hyperim- 
mune stimulation; and secondly, the analysis of the cellular derivation and of the 
biological  role  of neopterin  as  well  as  of other  components  of the  biopterin 
pathway.  This  second  research  topic  gained  further  importance  by the  most 
promising results of our recent clinical trials,  e.g. in the field of transplantation 
medicine  or  in  the  screening  for  patients  affected with  AIDS  (8-10).  In  this 
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TABLE II 
Capacity of Supernatants from Activated T Cells to Induce Neopterin 
Release from M4~ Is Completely Neutralized by Monoclonal Antibodies 
for IFN~ 
Neopterin re- 
Supernatants from:  Pretreated with:  lease from M4~* 
(pmol/ml) 
Medium  None  < 1 
T  cells stimulated with  None  13 
alloantigens  mcab IFNa2 25 ~g/ml  14 
mcab IFNa2a4 125 #g/ml  12 
mcab IFN~ 25 gg/ml  <1 
T  cells stimulated with  None  11 
PHA  mcab IFNa2 a4 25 #g/ml  13 
mcab IFNa~a4 125 ~g/ml  11 
mcab IFN7 25 #g/ml  <1 
* Induced with 25% supernatant, for details see Legend of Table I. 
response-associated elevation of neopterin. Results obtained with polyclonal and 
with monoclonal cellular reagents clearly demonstrate that monocytes and M4~ 
are in fact capable of producing neopterin when stimulated with supernatants 
from activated T  cells.  In recent experiments performed in cooperation with 
Drs.  Niederwieser and  Curtius  in  Zurich,  we could further support  this  new 
finding of the key role of M4~ in the production of immune response-associated 
neopterin by simultaneous demonstration of the induction of a pteridine-specific 
GTP cyclohydrolase.  2 In the same study we further observed that M4~ stimulated 
by T  cell-derived molecules are capable of completing this metabolic pathway 
and  synthesizing increased amounts of biopterin. ~ As  far as  the induction  of 
neopterin release from M4~ is concerned our in vitro data strongly point to the 
key role of interferon-gamma in the control of this phenomenon. This conclusion 
is supported by both the demonstration of neopterin release from M4~ by addition 
of hur IFN'y and the complete neutralization of the inducing capacity of T  cell 
supernatants  by monoclonal antibodies specific for hur IFNT.  It also became 
apparent that at least IFNa~ at much higher concentrations can induce neopterin 
release in vivo and in vitro. In this context it is of importance that high in vivo 
levels of acid-labile  and  thus  IFN7  like  interferon-a are  observed in  certain 
autoimmune diseases and in AIDS cases (14, 15). These states are also character- 
ized by elevated neopterin excretion (7,  10). In conclusion, we obtained in vitro 
evidence that immune response-associated neopterin release is a consequence of 
the activation of the biopterin synthetic pathway in Mq~ and that this process is 
under control of lymphokines. This in vitro model is in keeping with the above- 
discussed  clinical  findings  concerning in  vivo  interferon  levels  or  neopterin 
excretion in  relation  to disease states,  and with our previous observation  that 
lethally irradiated patients during the time of hemolymphatic aplasia are unable 
to  increase neopterin  excretion in  response  to  immune challenge (9).  It  also 
points  to  the  fact  that  a  metabolic  pathway  so  far  exclusively known  to  be 
involved in the generation of an essential cofactor of neurotransmitter synthesis 
is activated in bone marrow-derived cells during immune responses.  Whether 
2 Niederwieser,  A.,  G.  Sch6doon,  H.  G.  Curtius,  A.  Lang,  H.  Wachter,  Ch.  Huber.  Pteridine 
synthesis in mononuclear blood cells. Manuscript in preparation. HUBER ET AL.  315 
this represents a means by which immune cells communicate with each other or 
with the neuroendocrine system remains to be further investigated; in any case, 
recognition of signals emitted from this pathway in context with immune stimu- 
lation  might gain  clinically relevant  information about certain aspects  of the 
activation stage of the immune system itself. 
Summary 
Neopterin, a compound derived from GTP, represents a precursor molecule 
of biopterin that is an essential cofactor in neurotransmitter synthesis. We have 
recently reported that in vivo as well as in vitro immune responses are accom- 
panied by an increased release of neopterin and that this phenomenon can be 
used for the biochemical monitoring of diseases accompanied by hyperimmune 
stimulation. This article deals  with thecellular origin and the control of this 
immune response-associated neopterin release in vitro. Using highly purified or 
monoclonal cellular reagents we demonstrate that macrophages (M40 stimulated 
with supernatants from activated T  cells release large amounts of neopterin into 
culture  supernatants.  Further  experiments  involving  induction  of neopterin 
release from M4~ with various human recombinant interferons (IFNs) or neu- 
tralization of the effect of T  cell supernatants with various monoclonal anti-IFN 
antibodies revealed immune IFN as the active principle.  It thus appears that a 
metabolic pathway so far exclusively known in context with the generation of an 
essential cofactor of neurotransmitter-synthesis during immune responses is also 
activated in M4~ under stringent control by immune IFN-like lymphokines. 
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